Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies ...
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors Enara Bio’s EDAPT® platform is pioneering the discovery of Dark Antigens® – a …